FDA Questions the Efficacy of NeurogesX Capsaicin Patch
The FDA has raised questions about the efficacy of NeurogesX's prescription-strength capsaicin patch Qutenza in relieving pain related to nerve damage commonly associated with HIV, according to a Bloomberg Businessweek report.
The news sent the company's stock to its lowest level since March 2009. NeurogesX hasn't reported a profit since the company began selling shares in 2007, and the stock has fallen 83 percent in the past year.
Advisors are scheduled to meet with regulators tomorrow, and a final decision is expected by March 7.
Related Articles on Pain Management:
Study: Spinal Cord Stimulation Effective for HIV Neuropathy
Pain Center of Arizona Opens New Clinic in Phoenix
Pain Physicians: What is the Biggest Factor Contributing to Your Practice's Profitability?
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
Latest Articles
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,496.15 Trade time:4:05PM EDT Value change:▼6.66 (-0.05%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,850.12 Trade time:5:16PM EDT Value change:▲11.04 (0.39%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,318.86 Trade time:4:33PM EDT Value change:▲2.23 (0.17%)Channels
